SubjectWell

SubjectWell

Austin-based SubjectWell was founded in 2012 by Ivor Clarke to solve a persistent bottleneck in drug development: patient enrollment. While most sites and CROs rely on investigator networks and local advertising, SubjectWell assembled a national database of de-identified insurance claims and EHR data covering a reported 120 million Americans. This informs targeted, multi-channel outreach — email, social, and phone — that identifies patients before they ever visit a clinical site. The firm operates as a for-profit company rather than a family office; its capital has come from venture backers including Chicago Pacific Founders, Windham Venture Partners, and Healthy Ventures. SubjectWell connects pharmaceutical sponsors and CROs with pre-screened patient populations across more than 50 disease areas, with significant depth in cardiology, gastroenterology, CNS, and rare diseases. The company's double-opt-in marketplace allows patients to review trial details and consent to contact, which shifts screening burden upstream and compresses enrollment timelines. Its platform has supported trials ranging from Phase I oncology to large-scale vaccine studies, including participation in the U.S. government's Operation Warp Speed initiative during the COVID-19 pandemic. The firm does not conduct trials itself; it functions as a recruitment layer sitting between patients, sites, and sponsors. In June 2024, SubjectWell acquired Oligo Medic, a Canadian patient-recruitment firm specializing in rheumatology and underserved therapeutic areas (per the company's announcement, June 2024). The deal added bilingual North American outreach capability and a rheumatology-focused site network. This followed earlier geographic expansion into Canada and Western Europe. The company has not disclosed total capital raised; known funding rounds include a Series A led by Windham Venture Partners and a later round from Chicago Pacific Founders. Headcount is not publicly reported. SubjectWell's architecture differs from traditional site-management organizations in one critical respect: it owns a longitudinal patient-data asset rather than renting access campaign by campaign. That data moat — built over a decade of continuous aggregation — means the firm can identify trial-eligible patients for a sponsor even when those patients have no existing relationship with a particular investigator site. The unanswered question for the business is whether pharmaceutical companies will internalize this data-aggregation function over time or continue to buy it as a service.